Eleonora Restuccia | Semantic Scholar

Publications
Influence

Claim Your Author Page

Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.

First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE.

Thomas Bachelot, E. Ciruelos, +10 authors David Miles
2014

548^ Background: Combining P with 1st-line H + docetaxel (DOC) in pts with HER2-positive mBC significantly improved progression-free survival (PFS) and overall survival (OS) in the randomized phase… (More)

1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally…

David Miles, Fabio Puglisi, +6 authors Thomas Bachelot
2015

Abstract S3-04: Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus…

Grazia Arpino, J.-M. Ferrero, +4 authors Mothaffar F Rimawi
2017

Background: Preclinical and clinical evidence suggest that cross-talk between HER2 and estrogen receptor signaling pathways in breast cancer (BC) contributes to treatment resistance (Kaufman et al. J… (More)

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

Matteo Clavarezza, Monica Turazza, +11 authors Lucia Del Mastro
Breast
2013

BACKGROUND Neoadjuvant anthracycline- and taxane-based chemotherapy is frequently administered in breast cancer. Pathological complete response (pCR) rates vary according to clinical disease stage… (More)

Abstract P4-21-04: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

Thomas Bachelot, Fabio Puglisi, +6 authors David Miles
2017

Background: First-line (1L) docetaxel+trastuzumab+pertuzumab (THP) for HER2-positive metastatic breast cancer (MBC) significantly improved progression-free survival (PFS) and overall survival in the… (More)

361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC).

M. Andersson, Jose M. Lopez-Vega, +5 authors Edith A Perez
Annals of oncology : official journal of the…
2014

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1…

Edith A Perez, Jose M. Lopez-Vega, +5 authors Michael Andersson
Breast Cancer Research
2016

BackgroundPertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative chemotherapy partners are required… (More)

Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data

Vincenzo Adamo, Tindara Franchina, +6 authors Riccardo Ientile
2008

15036 Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate metabolism pathway. Two common genetic polymorphisms (C677T and A1298C) are associated with reduced MTHFR… (More)

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with…

José Baselga, Jennifer A. Petersen, +15 authors Sabina McGarrahan Gasper
2018

521Background: In APHINITY (NCT01358877), adding P to H + C significantly improved invasive disease-free survival in pts with HER2-positive EBC (von Minckwitz, NEJM 2017). Pt-reported health-related… (More)

Abstract P4-21-07: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast…

David Miles, Andreas Schneeweiss, +6 authors Thomas Bachelot
2017

Background: First-line (1L) docetaxel+trastuzumab+pertuzumab (THP) is approved for HER2-positive metastatic breast cancer (MBC), based on superior progression-free (PFS) and overall survival vs TH in… (More)